Hepatitis Monthly

Published by: Kowsar

Egy-Score Predicts Severe Hepatic Fibrosis and Cirrhosis in Egyptians With Chronic Liver Diseases: A Pilot Study

Mohamed A. Alboraie 1 , * , Mahmoud E. Afifi 1 , Fathy G. Elghamry 1 , Helmy A. Shalaby 1 , Gamal E. Elshennawy 1 , Ahmed A. Abdelaziz 1 , Mohamed U. Shaheen 2 and Amany R. Abo El-Seoud 3
Authors Information
1 Department of Internal Medicine, Al-Azhar University, Cairo, Egypt
2 Department of Clinical Pathology, Al-Azhar University, Cairo, Egypt
3 Department of Community Medicine and Public Health, Zagazig University, Zagazig, Egypt
Article information
  • Hepatitis Monthly: June 01, 2013, 13 (6); e10810
  • Published Online: June 16, 2013
  • Article Type: Research Article
  • Received: February 18, 2013
  • Revised: April 2, 2013
  • Accepted: April 20, 2013
  • DOI: 10.5812/hepatmon.10810

To Cite: Alboraie M A, Afifi M E, Elghamry F G, Shalaby H A, Elshennawy G E, et al. Egy-Score Predicts Severe Hepatic Fibrosis and Cirrhosis in Egyptians With Chronic Liver Diseases: A Pilot Study, Hepat Mon. 2013 ;13(6):e10810. doi: 10.5812/hepatmon.10810.

Abstract
Copyright © 2013, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Lai M, Afdhal NH. Editorial: staging liver fibrosis in hepatitis C: a challenge for this decade. Am J Gastroenterol. 2011; 106(12): 2121-2[DOI][PubMed]
  • 2. Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology. 2008; 134(6): 1670-81[DOI][PubMed]
  • 3. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004; 39(4): 1147-71[DOI][PubMed]
  • 4. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008; 371(9615): 838-51[DOI][PubMed]
  • 5. Jung KS, Kim SU. Clinical applications of transient elastography. Clin Mol Hepatol. 2012; 18(2): 163-73[DOI][PubMed]
  • 6. Rifai K, Cornberg J, Mederacke I, Bahr MJ, Wedemeyer H, Malinski P, et al. Clinical feasibility of liver elastography by acoustic radiation force impulse imaging (ARFI). Dig Liver Dis. 2011; 43(6): 491-7[DOI][PubMed]
  • 7. Huwart L, Sempoux C, Vicaut E, Salameh N, Annet L, Danse E, et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology. 2008; 135(1): 32-40[DOI][PubMed]
  • 8. Berzigotti A, Castera L. Update on ultrasound imaging of liver fibrosis. J Hepatol. 2013; [DOI][PubMed]
  • 9. Janssens F, de Suray N, Piessevaux H, Horsmans Y, de Timary P, Starkel P. Can transient elastography replace liver histology for determination of advanced fibrosis in alcoholic patients: a real-life study. J Clin Gastroenterol. 2010; 44(8): 575-82[DOI][PubMed]
  • 10. Kumar R, Rastogi A, Sharma MK, Bhatia V, Tyagi P, Sharma P, et al. Liver stiffness measurements in patients with different stages of nonalcoholic fatty liver disease: diagnostic performance and clinicopathological correlation. Dig Dis Sci. 2013; 58(1): 265-74[DOI][PubMed]
  • 11. Kitson MT, Kemp WW, Iser DM, Paul E, Wilson JW, Roberts SK. Utility of transient elastography in the non-invasive evaluation of cystic fibrosis liver disease. Liver Int. 2013; 33(5): 698-705[DOI][PubMed]
  • 12. Castera L. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat. 2009; 16(5): 300-14[DOI][PubMed]
  • 13. Hannivoort RA, Hernandez-Gea V, Friedman SL. Genomics and proteomics in liver fibrosis and cirrhosis. Fibrogenesis Tissue Repair. 2012; 5(1): 1[DOI][PubMed]
  • 14. Schoniger-Hekele M, Muller C. The combined elevation of tumor markers CA 19-9 and CA 125 in liver disease patients is highly specific for severe liver fibrosis. Dig Dis Sci. 2006; 51(2): 338-45[DOI][PubMed]
  • 15. Baranova A, Lal P, Birerdinc A, Younossi ZM. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol. 2011; 11: 91[DOI][PubMed]
  • 16. Omran MM, Farid K, Emran TM, Attallah AA. Fibro-alpha score as a simple and useful non-invasive test for predicting significant liver fibrosis in chronic hepatitis C patients. Arab J Gastroenterol. 2011; 12(2): 74-9[DOI][PubMed]
  • 17. El-Kamary SS, Mohamed MM, El-Raziky M, Shardell MD, Shaker OG, Elakel WA, et al. Liver fibrosis staging through a stepwise analysis of non-invasive markers (FibroSteps) in patients with chronic hepatitis C infection. Liver Int. 2013; [DOI][PubMed]
  • 18. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995; 22(6): 696-9[PubMed]
  • 19. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997; 349(9055): 825-32[PubMed]
  • 20. Ahmad W, Ijaz B, Gull S, Asad S, Khaliq S, Jahan S, et al. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Virol J. 2011; 8: 53[DOI][PubMed]
  • 21. Azer SA, Murray M, Farrell GC, Stacey NH. Selectivity and sensitivity of changes in serum bile acids during induction of cirrhosis in rats. Hepatology. 1993; 18(5): 1224-31[PubMed]
  • 22. Fontana RJ, Kleiner DE, Bilonick R, Terrault N, Afdhal N, Belle SH, et al. Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. Hepatology. 2006; 44(4): 925-35[DOI][PubMed]
  • 23. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002; 36(4 Pt 1): 986-92[DOI][PubMed]
  • 24. Naveau S, Poynard T, Benattar C, Bedossa P, Chaput JC. Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest. Dig Dis Sci. 1994; 39(11): 2426-32[PubMed]
  • 25. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003; 38(2): 518-26[DOI][PubMed]
  • 26. Rockey DC. Serologic markers of hepatic fibrosis. Gastroenterol Hepatol (N Y). 2008; 4(8): 539-41[PubMed]
  • 27. Cales P, Boursier J, Oberti F, Hubert I, Gallois Y, Rousselet MC, et al. FibroMeters: a family of blood tests for liver fibrosis. Gastroenterol Clin Biol. 2008; 32(6 Suppl 1): 40-51[DOI][PubMed]
  • 28. Poordad FF. FIBROSpect II: a potential noninvasive test to assess hepatic fibrosis. Expert Rev Mol Diagn. 2004; 4(5): 593-7[DOI][PubMed]
  • 29. Parkes J, Guha IN, Roderick P, Harris S, Cross R, Manos MM, et al. Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat. 2011; 18(1): 23-31[DOI][PubMed]
  • 30. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004; 127(6): 1704-13[PubMed]
  • 31. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem. 2005; 51(10): 1867-73[DOI][PubMed]
  • 32. Castera L. Non-invasive assessment of liver fibrosis in chronic hepatitis C. Hepatol Int. 2011; 5(2): 625-34[DOI][PubMed]
  • 33. Degos F, Perez P, Roche B, Mahmoudi A, Asselineau J, Voitot H, et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol. 2010; 53(6): 1013-21[DOI][PubMed]
  • 34. Abraldes JG, Araujo IK, Turon F, Berzigotti A. Diagnosing and monitoring cirrhosis: Liver biopsy, hepatic venous pressure gradient and elastography. Gastroenterol Hepatol. 2012; 35(7): 488-95[DOI][PubMed]
  • 35. Molina R, Filella X, Bruix J, Mengual P, Bosch J, Calvet X, et al. Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem. 1991; 37(8): 1379-83[PubMed]
  • 36. Giannini E, Borro P, Botta F, Chiarbonello B, Fasoli A, Malfatti F, et al. Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis. Int J Biol Markers. 2000; 15(3): 226-30[PubMed]
  • 37. Mann DV, Edwards R, Ho S, Lau WY, Glazer G. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol. 2000; 26(5): 474-9[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments